Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
42.96
-0.79 (-1.81%)
Aug 1, 2025, 4:00 PM - Market closed
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $22.10M in the quarter ending March 31, 2025, with 114.83% growth. This brings the company's revenue in the last twelve months to $58.89M, down -25.85% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$58.89M
Revenue Growth
-25.85%
P/S Ratio
56.46
Revenue / Employee
$313,218
Employees
188
Market Cap
3.01B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
KYMR News
- 5 weeks ago - Kymera Therapeutics Announces Pricing of $250 Million Public Offering - GlobeNewsWire
- 5 weeks ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 5 weeks ago - Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics - Reuters
- 5 weeks ago - Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update - GlobeNewsWire
- 5 weeks ago - Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders - Business Wire
- 2 months ago - Wall Street Shows Love for Kymera Stock After Biotech's Promising Drug Trial - Barrons
- 2 months ago - Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data - Seeking Alpha
- 2 months ago - Kymera Stock Jumps. New Dermatitis Pill Could Challenge Regeneron Blockbuster. - Barrons